Press releases

2021

February

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.

January

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

2019

February

Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.

2018

November

Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor

January

Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial

2017

November

Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex on Scandinavian markets

Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression

Stable business foundation with a good prospect for presence in new European markets.

September

Steady income and positive sales dynamics of Celon Pharma S.A. in the first half of 2017

July

Celon Pharma S.A. submitted an application for a permit to build a Research and Development Centre in Kazuń Nowy.

Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing innovative medicinal products

May

Celon Pharma S.A. reports a stable first quarter of 2017 and its plans for the dynamic development of the Company's operations in the current year.

A new Research and Development Centre of Celon Pharma S.A.

Global commercialisation of Celon Pharma S.A.’s innovative portfolio

April

Celon Pharma S.A. reports a steadily growing revenue and profit for 2016

February

Celon Pharma S.A. received an award for the best stock debut in 2016